Abstract

Metastasis is one of the most common causes of death in patients with colorectal cancer (CRC). Block of proliferation 1 (BOP1) regulates tumorigenesis, epithelial‐to‐mesenchymal transition, migration, metastasis, and drug resistance in several tumor types. However, the role of BOP1 in the regulation of colorectal cancer cell migration and invasion is still largely unclear. In this study, the results of immunohistochemistry showed that BOP1 was upregulated in our cohort of CRC patients. BOP1 knockdown inhibited the migration and invasion of CRC cells, confirmed by the downregulation of the mRNA levels of MMP‐2 and MMP‐9. The overexpression of BOP1 in CRC cells exerted the opposite effect. SP600125, an inhibitor of JNK signaling, partially abolished the BOP1 overexpression‐mediated increase in the migratory and invasive ability of CRC cells. Our results indicated that BOP1 is an important regulator of CRC cell invasion and migration, predominantly through the JNK signaling pathway.

Highlights

  • Colorectal cancer (CRC) is one of the most common gastrointestinal tumors and occurs in the colon or rectum.[1,2,3] Metastasis has been reported as the most common cause of death in patients with CRC.[46]

  • There was no association between Block of proliferation 1 (BOP1) expression in tissues of CRC patients and age, gender, or tumor size

  • These clinical results showed that BOP1 overexpression in CRC patients might be associated with CRC aggressiveness, especially tumor metastasis

Read more

Summary

| INTRODUCTION

Colorectal cancer (CRC) is one of the most common gastrointestinal tumors and occurs in the colon or rectum.[1,2,3] Metastasis has been reported as the most common cause of death in patients with CRC.[46]. It is necessary to determine the role of BOP1 in tumor progression, especially in migration and invasion of cancer. BOP1 promoted CRC cell migration and invasion by regulating the JNK pathway. Our results suggest that BOP1 is an important regulator of CRC cell invasion and migration, predominantly through the JNK signaling pathway, and raise the possibility of using this molecule as an indicator for CRC treatment

| MATERIALS AND METHODS
Findings
| DISCUSSION
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call